Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma

Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma

DDR1 has been identified as a cancer‐associated receptor tyrosine kinase that is highly expressed in several malignancies relative to normal tissues. Clinically approved multi‐kinase inhibitors, such as nilotinib, inhibit DDR1‐mediated tumor growth in xenograft models, suggesting DDR1 might be a pot...

Full description

Bibliographic Details
Main Authors: Yiran Tao, Ruixue Wang, Qinhuai Lai, Mengdan Wu, Yuxi Wang, Xiaohua Jiang, Lishi Zeng, Shijie Zhou, Zhongping Li, Tinghan Yang, Yuqin Yao, Yangping Wu, Lin Yu, Yuyin Fu, Weirong Lai, Yujia Peng, Ying Lu, Zhixiong Zhang, Cuiyu Guo, Guangbing Zhang, Lantu Gou, Jinliang Yang
Format: Article
Language:English
Published: Wiley 2019-09-01
Series:Molecular Oncology
Subjects:
antibody‐drug conjugate
colon cancer
receptor tyrosine kinase
resistance
xenograft tumor model
Online Access:https://doi.org/10.1002/1878-0261.12520

Internet

https://doi.org/10.1002/1878-0261.12520

Similar Items